Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden;
Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
Clin Chem. 2017 Aug;63(8):1409-1417. doi: 10.1373/clinchem.2017.271890. Epub 2017 Jun 14.
Cardiac troponin (cTn) is important for risk assessment in patients with suspected acute coronary syndrome (ACS). cTn concentrations may, however, be affected by renal dysfunction, and the clinical importance of this interrelation is not well established. We investigated the association between cTnT and cTnI (measured with conventional assays and a more sensitive assay) with the estimated glomerular filtration rate (eGFR) and also assessed the ability of cTn to predict the 1-year all-cause mortality.
This retrospective registry-based study used data from 309454 admissions to Swedish coronary care units. cTn associations with eGFR and mortality were assessed using different regression models and by calculating multivariable-adjusted -statistics.
cTnT concentrations exhibited stronger associations with eGFR than cTnI concentrations (conventional cTnT assay: β = -0.113; more sensitive cTnT assay: β= -0.186; pooled conventional cTnI assays: β = -0.098). Overall, cTnT provided greater prognostic accuracy than cTnI. This was most evident in non-ACS patients with normal or mildly reduced eGFR when using the more sensitive assay. Despite higher mortality rates, no consistent increases in the -statistics of cTn were seen with severely reduced eGFR irrespective of the presence of ACS or non-ACS.
cTnT concentrations exhibited stronger associations with reduced eGFR than cTnI concentrations in patients admitted because of suspected ACS. cTnT, particularly when measured using the more sensitive assay, also tended to be a stronger prognosticator. However, the relative significance of the obtained results must be considered in the context of the severity of renal dysfunction and whether ACS is present.
心肌肌钙蛋白(cTn)对疑似急性冠状动脉综合征(ACS)患者的风险评估很重要。然而,cTn 浓度可能受到肾功能障碍的影响,这种相互关系的临床重要性尚未得到充分确立。我们研究了 cTnT 和 cTnI(用常规检测和更敏感的检测方法测量)与估计肾小球滤过率(eGFR)之间的关联,并评估了 cTn 预测 1 年全因死亡率的能力。
这项基于回顾性登记的研究使用了来自瑞典冠状动脉护理病房 309454 例住院患者的数据。使用不同的回归模型和计算多变量校正的统计量来评估 cTn 与 eGFR 和死亡率的相关性。
cTnT 浓度与 eGFR 的相关性强于 cTnI 浓度(常规 cTnT 检测:β=-0.113;更敏感的 cTnT 检测:β=-0.186;综合常规 cTnI 检测:β=-0.098)。总体而言,cTnT 比 cTnI 提供了更高的预后准确性。当使用更敏感的检测方法时,这种情况在 eGFR 正常或轻度降低的非 ACS 患者中最为明显。尽管死亡率较高,但无论是否存在 ACS,严重肾功能减退的患者 cTn 的统计量均未见一致增加。
与 cTnI 浓度相比,疑似 ACS 住院患者的 cTnT 浓度与 eGFR 降低的相关性更强。cTnT,尤其是当使用更敏感的检测方法时,也往往是一个更强的预后指标。然而,在考虑肾功能障碍的严重程度以及是否存在 ACS 的情况下,必须考虑获得的结果的相对重要性。